

DCAT[®]

TOP INDUSTRY NEWS

This week's issue is sponsored by CordenPharma International GmbH



**FULL-SERVICE CDMO >>
FOR A GLOBAL MARKET**
Proud Sponsors of DCAT Week '20

CORDENPHARMA
www.cordenpharma.com

- ▶ **[AbbVie Moves Closer to Finalizing Pending \\$63-Bn Acquisition of Allergan](#)**
The European Commission has approved Allergan's divestiture of brazikumab, a condition of final EU approval of AbbVie's pending \$63-billion acquisition of Allergan. [Read More >](#)
- ▶ **[Gilead To Acquire Immuno-Oncology Company Forty Seven for \\$4.9 Bn](#)**
Gilead Sciences has agreed to acquire Forty Seven, Inc., a clinical-stage immuno-oncology company, for \$4.9 billion. [Read More >](#)
- ▶ **[Biogen, Sangamo in \\$2.72-Bn Deal for Gene-Regulation Therapies](#)**
Biogen and Sangamo Therapeutics have formed a global licensing collaboration pact for gene-regulation therapies in neurology in a deal worth up to \$2.72 billion. [Read More >](#)
- ▶ **[Takeda Divesting Select OTC and Rx Drugs in Three Deals Totaling \\$1.7 Bn](#)**
As part of a plan to reduce debt following its \$62-billion acquisition of Shire, Takeda has moved on the sale of select OTC and Rx drugs for \$1.7 billion. [Read More >](#)
- ▶ **[FDA Reports One Drug in Shortage Due to Mfg Issues Related to Coronavirus](#)**
As part of its supply-chain surveillance plan for the novel coronavirus, the FDA reports one drug in shortage due to an API manufacturing site affected by the virus. [Read More >](#)
- ▶ **[White House Meets with Executives for Coronavirus Treatments](#)**
President Donald Trump and executives discuss progress and needs in advancing vaccines and treatments against coronavirus; also, news from Takeda and Vir Biotechnology. [Read More >](#)
- ▶ **[AstraZeneca Completes Sale of Five Hypertension Drugs for \\$350 M](#)**
AstraZeneca has completed an agreement to divest its global commercial rights for five established hypertension medicines to Atrahs Pharma for \$350 million. [Read More >](#)
- ▶ **[Takeda Acquires PVP Biologics for Up to \\$330 Million](#)**
Takeda Pharmaceutical has acquired PVP Biologics, a San Diego-based company developing treatments for celiac disease, in a deal worth up to \$330 million. [Read More >](#)



Top Industry News is published and distributed weekly to DCAT member companies, Visit www.dcat.org.



Drug, Chemical & Associated Technologies Association
One Union Street, Suite 208, Robbinsville, NJ 08691

[Unsubscribe](#) or update your subscription options.